Publications by authors named "Nigel Vicker"

Claim this Profile
S
Substituted Aryl Benzylamines as Potent and Selective Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 3.
Nigel Vicker, Helen V Bailey, Joanna M Day, Mary F Mahon, Andrew Smith

Molecules· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid and Efficient Microwave-Assisted Friedländer Quinoline Synthesis.
Helen V Bailey, Mary F Mahon, Nigel Vicker, Barry V L Potter

ChemistryOpen· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Joanna M Day, Paul A Foster, Helena J Tutill, Fabien Schmidlin, Christopher M Sharland, Nigel Vicker

Endocr Relat Cancer· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Xiangdong Su, Heather A Halem, Mark P Thomas, Cecile Moutrille, Michael D Culler, Nigel Vicker

Bioorg Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
Xiangdong Su, Fabienne Pradaux-Caggiano, Nigel Vicker, Mark P Thomas, Heather Halem

ChemMedChem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Xiangdong Su, Nigel Vicker, Mark P Thomas, Fabienne Pradaux-Caggiano, Heather Halem

ChemMedChem· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
Xiangdong Su, Fabienne Pradaux-Caggiano, Mark P Thomas, Michelle W Y Szeto, Heather A Halem, Nigel Vicker

ChemMedChem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Xiangdong Su, Nigel Vicker, Barry V L Potter

Prog Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Nigel Vicker, Christopher M Sharland, Wesley B Heaton, Ana M Ramos Gonzalez, Helen V Bailey

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Xiangdong Su, Nigel Vicker, Melanie Trusselle, Heather Halem, Michael D Culler

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Joanna M Day, Helena J Tutill, Paul A Foster, Helen V Bailey, Wesley B Heaton, Nigel Vicker

Mol Cell Endocrinol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
Joanna M Day, Paul A Foster, Helena J Tutill, Michael F C Parsons, Simon P Newman, Nigel Vicker

Int J Cancer· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design.
Gillian M Allan, Nigel Vicker, Harshani R Lawrence, Helena J Tutill, Joanna M Day

Bioorg Med Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Nigel Vicker, Xiangdong Su, Dharshini Ganeshapillai, Andrew Smith, Atul Purohit

J Steroid Biochem Mol Biol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of human and rat 11beta-hydroxysteroid dehydrogenase type 1 by 18beta-glycyrrhetinic acid derivatives.
Xiangdong Su, Nigel Vicker, Harshani Lawrence, Andrew Smith, Atul Purohit

J Steroid Biochem Mol Biol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Nigel Vicker, Harshani R Lawrence, Gillian M Allan, Christian Bubert, Andrew Smith

ChemMedChem· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Xiangdong Su, Nigel Vicker, Dharshini Ganeshapillai, Andrew Smith, Atul Purohit

Mol Cell Endocrinol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Gillian M Allan, Christian Bubert, Nigel Vicker, Andrew Smith, Helena J Tutill

Mol Cell Endocrinol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.
Joanna M Day, Helena J Tutill, Simon P Newman, Atul Purohit, Harshani R Lawrence, Nigel Vicker

Mol Cell Endocrinol· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Gillian M Allan, Harshani R Lawrence, Josephine Cornet, Christian Bubert, Delphine S Fischer, Nigel Vicker

J Med Chem· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Delphine S Fischer, Gillian M Allan, Christian Bubert, Nigel Vicker, Andrew Smith

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Harshani R Lawrence, Nigel Vicker, Gillian M Allan, Andrew Smith, Mary F Mahon

J Med Chem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases.
Xiangdong Su, Harshani Lawrence, Dharshini Ganeshapillai, Adrian Cruttenden, Atul Purohit, Nigel Vicker

Bioorg Med Chem· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel 18 beta-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11 beta-hydroxysteroid dehydrogenase 2.
Nigel Vicker, Xiangdong Su, Harshani Lawrence, Adrian Cruttenden, Atul Purohit

Bioorg Med Chem Lett· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance.
Shouming Wang, Adrian Folkes, Irina Chuckowree, Xiaoling Cockcroft, Sukhjit Sohal, Nigel Vicker

J Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis